Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Ulrike Nitz,Doris Augustin,Matthias Christgen,Rachel Wuerstlein,Claudia Schumacher,Andreas Kohls,Hans Holger Fischer,Michael Wilhelm Braun,Eva-Maria Grischke,Katja Krauss,Jochem Potenberg,Cornelia Liedtke,Toralf Reimer,Andrea Stefek,Oleg Gluz,Sherko Kümmel,Helmut Forstbauer,Hans Heinrich Kreipe,Nadia Harbeck

doi:10.1200/jco.2016.34.15_suppl.518

Abstract

518Background: In HER2+ EBC pCR rates after neoadjuvant chemo (CT)+/- anti-HER2 therapy differ according to hormone receptor (HR) status. The neoadjuvant ADAPT HER2+/HR- phase II trial aims to iden...

Full Text

Published version (

Free)

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

R Discovery Prime

R Discovery Prime

Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Abstract

Talk to us

Similar Papers

More From: Journal of Clinical Oncology

Lead the way for us

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 8

Similar Papers

Research advancement in the 41st San Antonio Breast Cancer Symposium

-

01 Jun 2019
01 Jun 2019

Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results
...
Translational Cancer Research | VOL. 5
, et. al. ...
31 Oct 2016
Translational Cancer Research | VOL. 5

Ανάλυση κόστους - αποτελεσματικότητας του Pertuzumab έναντι εικονικού φαρμάκου σε HER2 θετικό μεταστατικό καρκίνο του μαστού

-

16 Nov 2020
16 Nov 2020

Analysis of eddicacy of HER2-enriched subtype to Trastuzumab combined with Lapatinib in treatment of early breast cancer
...
International journal of surgery (London, England) | VOL. 46
, et. al. ...
15 May 2019
International journal of surgery (London, England) | VOL. 46

Editage

Paperpal

R Discovery

Mind the Graph

R Discovery Prime

R Discovery Prime

Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Abstract

Talk to us

Similar Papers

More From: Journal of Clinical Oncology